At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
sipuleucel-T +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating sipuleucel-T and DNA Vaccine for Prostate Cancer. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This randomized pilot clinical trial studies sipuleucel-T with or without deoxyribonucleic acid (DNA) vaccine therapy in treating patients with prostate cancer that has not responded to previous treatment with hormones and has spread to other places in the body. Vaccines may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving sipuleucel-T vaccine works better with or without DNA vaccine therapy in treating prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsDendreon
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartMay 2013
Primary CompletionJun 2017
Study CompletionAug 2020
TodayJul 2026
First PostedOct 15, 2012
Enrollment StartMay 20, 2013
Primary CompletionJun 12, 2017
Study CompletionAug 13, 2020
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 13.7 years ago
Interventions
sipuleucel-Tbiological
Given IV
DNA Vaccinebiological
Given ID